However, the enzyme DPP-4 rapidly degrades circulating GLP-1, limiting its duration of action
This directly complicates patient screening and enrollment, leads to substantially lower overall expected efficacy compared with patients harboring upstream genetic defects (such as POMC deficiency) [56] , and results in a low statistical success rate in large-scale trials
Anti-sympathetic drugs, such as -blockers, may represent suitable candidates in combination with DPP-4 for the treatment of hypertension with which to prevent sympathetic activity
I want to optimize cellular function, metabolism, and feel more energetic
Clinical Associate Professor of Plastic Surgery at Texas Tech University Health Sciences Center, teaching the same techniques I use every week